Shalini Kavita Vinod

Shalini Kavita Vinod

Auto-generated profile, based on publicly available information

Shalini Kavita Vinod

School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, Australia

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Respirology
Verified
Journal Article
Open access
PDF file
SVShalini K. Vinod
Shalini K. Vinod
EHEric Hau
Eric Hau
Radiotherapy is an important modality used for the treatment of lung cancer. Seventy‐seven percent of all patients with lung cancer have an evidence‐based indication for radiotherapy, although it is often underutilized. Radiotherapy can be used as curative or palliative treatment across all stages of disease. Technological advances have allowed better radiotherapy targeting of tumours and reduced incidental irradiation of surrounding normal tissues. This has expanded the indications for radiotherapy in lung cancer and improved outcomes both in terms of increasing survival and reducing toxicity. This review examines the current role of radiotherapy in lung cancer, discusses the evidence behind this and identifies future directions in the radiotherapy treatment of lung cancer.

1 November 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SVShalini K. Vinod
Shalini K. Vinod
MJMichael G. Jameson
Michael G. Jameson
MMMyo Min
Myo Min
LHLois C. Holloway
Lois C. Holloway

1 October 2013 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
PMP. Metcalfe
P. Metcalfe
GLG. P. Liney
G. P. Liney
LHLois Holloway
Lois Holloway
AWA. Walker
A. Walker
MBM. Barton
M. Barton
WTW. Tomé
W. Tomé
The exquisite soft-tissue contrast of magnetic resonance imaging (MRI) has meant that the technique is having an increasing role in contouring the gross tumor volume (GTV) and organs at risk (OAR) in radiation therapy treatment planning systems (TPS). MRI-planning scans from diagnostic MRI scanners are currently incorporated into the planning process by being registered to CT data. The soft-tissue data from the MRI provides target outline guidance and the CT provides a solid geometric and electron density map for accurate dose calculation on the TPS computer. There is increasing interest in MRI machine placement in radiotherapy clinics as an adjunct to CT simulators. Most vendors now offer 70 cm bores with flat couch inserts and specialised RF coil designs. We would refer to these devices as MR-simulators. There is also research into the future application of MR-simulators independent of CT and as in-room image-guidance devices. It is within the background of this increased interest in the utility of MRI in radiotherapy treatment planning that this paper is couched. The paper outlines publications that deal with standard MRI sequences used in current clinical practice. It then discusses the potential for using processed functional diffusion maps (fDM) derived from diffusion weighted image sequences in tracking tumor activity and tumor recurrence. Next, this paper reviews publications that describe the use of MRI in patient-management applications that may, in turn, be relevant to radiotherapy treatment planning. The review briefly discusses the concepts behind functional techniques such as dynamic contrast enhanced (DCE), diffusion-weighted (DW) MRI sequences and magnetic resonance spectroscopic imaging (MRSI). Significant applications of MR are discussed in terms of the following treatment sites: brain, head and neck, breast, lung, prostate and cervix. While not yet routine, the use of apparent diffusion coefficient (ADC) map analysis indicates an exciting future application for functional MRI. Although DW-MRI has not yet been routinely used in boost adaptive techniques, it is being assessed in cohort studies for sub-volume boosting in prostate tumors.

11 May 2016 in Journal of Medical Imaging and Radiation Oncology
Verified
Journal Article
Closed access
SVShalini K Vinod
Shalini K Vinod
MMMyo Min
Myo Min
MJMichael G Jameson
Michael G Jameson
LHLois C Holloway
Lois C Holloway

26 April 2011 in Cancer
Verified
Journal Article
Closed access
PDF file
MBMiriam M. Boxer
Miriam M. Boxer
SVShalini K. Vinod
Shalini K. Vinod
JSJesmin Shafiq
Jesmin Shafiq
KDKirsten J. Duggan
Kirsten J. Duggan

29 April 2015 in Psycho-Oncology
Verified
Journal Article
Open access
PDF file
SCSuzanne K. Chambers
Suzanne K. Chambers
Peter BaadePeter Baade
Peter Baade
PYPhilippa Youl
Philippa Youl
JAJoanne Aitken
Joanne Aitken
SOStefano Occhipinti
Stefano Occhipinti
DODianne L. O'COnnell
Dianne L. O'COnnell
Objective Health-related stigma is associated with negative psychological and quality of life outcomes in lung cancer patients. This study describes the impact of stigma on lung cancer patients' psychological distress and quality of life and explores the role of social constraints and illness appraisal as mediators of effect. Methods A self-administered cross-sectional survey examined psychological distress and quality of life in 151 people (59% response rate) diagnosed with lung cancer from Queensland and New South Wales. Health-related stigma, social constraints and illness appraisals were assessed as predictors of adjustment outcomes. Results Forty-nine percent of patients reported elevated anxiety; 41% were depressed; and 51% had high global distress. Health-related stigma was significantly related to global psychological distress and quality of life with greater stigma and shame related to poorer outcomes. These effects were mediated by illness appraisals and social constraints. Conclusions Health-related stigma appears to contribute to poorer adjustment by constraining interpersonal discussions about cancer and heightening feelings of threat. There is a need for the development and evaluation of interventions to ameliorate the negative effects of health-related stigma among lung cancer patients. © 2015 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.